Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cannabix Technologies Inc C.BLO

Alternate Symbol(s):  BLOZF

Cannabix Technologies Inc. is a Canada-based developer of marijuana and alcohol breathalyzer technologies for law enforcement, workplaces and laboratories. The Company is working to develop delta-9 tetrahydrocannabinol (THC) and alcohol screening devices. Delta-9 THC is the psychoactive component of marijuana. Breath testing for delta-9 THC would allow employers and law enforcement to identify recent marijuana use. It develops contactless breath alcohol detection devices. Its technologies include THC Breathalyzer System, Breath Logix Alcohol Breathalyzer and Breath Logix Vehicle. THC Breathalyzer System includes Cannabix Mass Spectrum (MS) Breath Sampler (MSBS) and Cannabix Breath Collection Unit (BCU). The Breath Logix (BR-LGX) Industrial Series is a fully automated breath alcohol screening system for employee, contractor and visitor access control. The BR-LGX vehicle device could be integrated into various locations in the vehicle cabin. It also develops Cannabix FAIMS device.


CSE:BLO - Post by User

Post by C10H12N2on Jun 27, 2022 2:39am
443 Views
Post# 34783795

BUT WAIT...THERE'S MORE STINK TO HIGH HEAVEN

BUT WAIT...THERE'S MORE STINK TO HIGH HEAVENSTINK TO HIGH HEAVEN



IMO, only a fool would continue sitting on their hands and knees watching their chances at a decent ROI slip away because of ongoing shenanigans @ virtual office HQ. What further shenanigans do you need to endure before taking action, another 100 to 1 reverse split in 2023?

CONTACT INFORMATION
Christopher J. Moreau
CEO
Algernon Pharmaceuticals Inc.
604.398.4175 ext 701
info@algernonpharmaceuticals.com
investors@algernonpharmaceuticals.com
www.algernonpharmaceuticals.com

I will reiterate once again, your chances of getting any significant ROI will come down to what decision management makes with the proceeds from the Public Offering. If they decide to barrel ahead with Phase 1 studies you are toast for at least the next 5 years. If they do the right and obvious thing, they will take the money and run a Gold Standard Phase 2 study for Chronic Cough in the USA ASAP.

Chronic Cough is the fast track to a billion dollar market cap. Moreau cannot point to any other faster avenue if one even exists with Cancer or Stroke or CKD. They're all long shots far off into the distant future. Chronic Cough is here and now. Strike while the iron is hot (momentum and market interest) and finally give Bellus Health a run for the money versus blowing hot are on webcast claiming Bellus Health is a pure comparison to Algernon Pharmaceuticals.

Prove it in Words and Deeds Christopher Moreau (CEO).

Good Luck To All In All Your Endeavors In Life.
<< Previous
Bullboard Posts
Next >>